Obel N - Search Results

1

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE); Costagliola D, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, de Luca A, Jansen K, De Wit S, Obel N, Fätkenheuer G, Touloumi G, Mussini C, Castagna A, Stephan C, García F, Zangerle R, Duval X, Perez-Hoyos S, Meyer L, Ghosn J, Fabre-Colin C, Kjaer J, Chêne G, Grarup J, Phillips A, Lodwick R, Torti C, Dorrucci M, Günthard HF, Michalik C, Chrysos G, Castagna A. Pursuing Later Treatment Option II (PLATO II) Project Team of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), et al. Among authors: obel n. J Infect Dis. 2013 Mar 1;207(5):759-67. doi: 10.1093/infdis/jis752. Epub 2012 Dec 7. J Infect Dis. 2013. PMID: 23225900

2

Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.

Jensen-Fangel S, Kirk O, Larsen L, Blaxhult A, Gerstoft J, Pedersen C, Black FT, Lundgren JD, Obel N. Jensen-Fangel S, et al. Among authors: obel n. Scand J Infect Dis. 1999;31(5):489-93. doi: 10.1080/00365549950164021. Scand J Infect Dis. 1999. PMID: 10576129

3

The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.

Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Møller A, Sørensen HT, Obel N. Jensen-Fangel S, et al. Among authors: obel n. Clin Infect Dis. 2002 Dec 15;35(12):1541-8. doi: 10.1086/344769. Epub 2002 Dec 3. Clin Infect Dis. 2002. PMID: 12471575

4

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD; MaxCmin1 Trial Group. Dragsted UB, et al. Among authors: obel n. J Infect Dis. 2003 Sep 1;188(5):635-42. doi: 10.1086/377288. Epub 2003 Aug 20. J Infect Dis. 2003. PMID: 12934178 Clinical Trial.

5

Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD. Gerstoft J, et al. Among authors: obel n. AIDS. 2003 Sep 26;17(14):2045-52. doi: 10.1097/00002030-200309260-00005. AIDS. 2003. PMID: 14502007 Clinical Trial.

6

Use of the protease inhibitor saquinavir hard gel in human immunodeficiency virus-infected patients in the early period of highly active antiretroviral therapy: does it affect long-term treatment outcome?

Jensen-Fangel S, Pedersen C, Nielsen H, Tauris P, Møller A, Sørensen HT, Obel N. Jensen-Fangel S, et al. Among authors: obel n. Scand J Infect Dis. 2003;35(10):743-9. doi: 10.1080/00365540310016187. Scand J Infect Dis. 2003. PMID: 14606614

7

A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

Kirk O, Lundgren JD, Pedersen C, Mathiesen LR, Nielsen H, Katzenstein TL, Obel N, Gerstoft J. Kirk O, et al. Among authors: obel n. Antivir Ther. 2003 Dec;8(6):595-602. Antivir Ther. 2003. PMID: 14760893 Clinical Trial.

8

Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients.

Lerbaek A, Kristiansen TB, Katzenstein TL, Mathiesen L, Gerstoft J, Nielsen C, Larsen K, Nielsen JO, Obel N, Laursen AL, Nielsen SD. Lerbaek A, et al. Among authors: obel n. Scand J Infect Dis. 2004;36(4):280-6. doi: 10.1080/00365540410019633. Scand J Infect Dis. 2004. PMID: 15198185 Clinical Trial.

9

Low effectiveness of highly active antiretroviral therapy and high mortality in the Greenland HIV-infected population.

Lohse N, Ladefoged K, Pedersen L, Jensen-Fangel S, Sørensen HT, Obel N. Lohse N, et al. Among authors: obel n. Scand J Infect Dis. 2004;36(10):738-42. doi: 10.1080/00365540410020974. Scand J Infect Dis. 2004. PMID: 15513400

10

Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study.

Lohse N, Hansen AB, Jensen-Fangel S, Kronborg G, Kvinesdal B, Pedersen C, Larsen CS, Møller A, Willumsen L, Obel N. Lohse N, et al. Among authors: obel n. Scand J Infect Dis. 2005;37(5):338-43. doi: 10.1080/00365540510031692. Scand J Infect Dis. 2005. PMID: 16051569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

437 results

Search Page

Filters